These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 28183185)
1. Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome. Totaro KA; Barthelme D; Simpson PT; Jiang X; Lin G; Nathan CF; Sauer RT; Sello JK ACS Infect Dis; 2017 Feb; 3(2):176-181. PubMed ID: 28183185 [TBL] [Abstract][Full Text] [Related]
2. Macrocyclic Peptides that Selectively Inhibit the Zhang H; Hsu HC; Kahne SC; Hara R; Zhan W; Jiang X; Burns-Huang K; Ouellette T; Imaeda T; Okamoto R; Kawasaki M; Michino M; Wong TT; Toita A; Yukawa T; Moraca F; Vendome J; Saha P; Sato K; Aso K; Ginn J; Meinke PT; Foley M; Nathan CF; Darwin KH; Li H; Lin G J Med Chem; 2021 May; 64(9):6262-6272. PubMed ID: 33949190 [TBL] [Abstract][Full Text] [Related]
3. Substrate-guided optimization of the syringolins yields potent proteasome inhibitors with activity against leukemia cell lines. Totaro KA; Barthelme D; Simpson PT; Sauer RT; Sello JK Bioorg Med Chem; 2015 Sep; 23(18):6218-22. PubMed ID: 26296913 [TBL] [Abstract][Full Text] [Related]
4. Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome. Hsu HC; Singh PK; Fan H; Wang R; Sukenick G; Nathan C; Lin G; Li H Biochemistry; 2017 Jan; 56(1):324-333. PubMed ID: 27976853 [TBL] [Abstract][Full Text] [Related]
5. Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome. Desvergne A; Genin E; Maréchal X; Gallastegui N; Dufau L; Richy N; Groll M; Vidal J; Reboud-Ravaux M J Med Chem; 2013 Apr; 56(8):3367-78. PubMed ID: 23540790 [TBL] [Abstract][Full Text] [Related]
6. Selective Phenylimidazole-Based Inhibitors of the Zhan W; Hsu HC; Morgan T; Ouellette T; Burns-Huang K; Hara R; Wright AG; Imaeda T; Okamoto R; Sato K; Michino M; Ramjee M; Aso K; Meinke PT; Foley M; Nathan CF; Li H; Lin G J Med Chem; 2019 Oct; 62(20):9246-9253. PubMed ID: 31560200 [TBL] [Abstract][Full Text] [Related]
7. Design, Synthesis, and Biological Activity of Isosyringolin A. Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978 [TBL] [Abstract][Full Text] [Related]
8. Noncovalent inhibitors of human 20S and 26S proteasome based on trypsin inhibitor SFTI-1. Dębowski D; Cichorek M; Lubos M; Wójcik S; Łęgowska A; Rolka K Biopolymers; 2016 Sep; 106(5):685-96. PubMed ID: 27258473 [TBL] [Abstract][Full Text] [Related]
9. Systematic Analyses of Substrate Preferences of 20S Proteasomes Using Peptidic Epoxyketone Inhibitors. Huber EM; de Bruin G; Heinemeyer W; Paniagua Soriano G; Overkleeft HS; Groll M J Am Chem Soc; 2015 Jun; 137(24):7835-42. PubMed ID: 26020686 [TBL] [Abstract][Full Text] [Related]
10. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes. de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746 [TBL] [Abstract][Full Text] [Related]
11. Mycobacterium tuberculosis prcBA genes encode a gated proteasome with broad oligopeptide specificity. Lin G; Hu G; Tsu C; Kunes YZ; Li H; Dick L; Parsons T; Li P; Chen Z; Zwickl P; Weich N; Nathan C Mol Microbiol; 2006 Mar; 59(5):1405-16. PubMed ID: 16468985 [TBL] [Abstract][Full Text] [Related]
12. Structural basis for the assembly and gate closure mechanisms of the Mycobacterium tuberculosis 20S proteasome. Li D; Li H; Wang T; Pan H; Lin G; Li H EMBO J; 2010 Jun; 29(12):2037-47. PubMed ID: 20461058 [TBL] [Abstract][Full Text] [Related]
13. Modulation of proteasome subunit selectivity of syringolins. Tatsumi K; Kitahata S; Komatani Y; Katsuyama A; Yakushiji F; Ichikawa S Bioorg Med Chem; 2024 May; 106():117733. PubMed ID: 38704960 [TBL] [Abstract][Full Text] [Related]
14. Insight into Inhibitor Binding in the Eukaryotic Proteasome: Computations of the 20S CP. Hodošček M; Elghobashi-Meinhardt N Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30514002 [TBL] [Abstract][Full Text] [Related]
15. Identification of plant-derived natural products as potential inhibitors of the Mycobacterium tuberculosis proteasome. Zheng Y; Jiang X; Gao F; Song J; Sun J; Wang L; Sun X; Lu Z; Zhang H BMC Complement Altern Med; 2014 Oct; 14():400. PubMed ID: 25315519 [TBL] [Abstract][Full Text] [Related]
16. Computational inhibition studies of the human proteasome by argyrin-based analogues with subunit specificity. Loizidou EZ; Zeinalipour-Yazdi CD Chem Biol Drug Des; 2014 Jul; 84(1):99-107. PubMed ID: 24521156 [TBL] [Abstract][Full Text] [Related]
17. Structure of the Mycobacterium tuberculosis proteasome and mechanism of inhibition by a peptidyl boronate. Hu G; Lin G; Wang M; Dick L; Xu RM; Nathan C; Li H Mol Microbiol; 2006 Mar; 59(5):1417-28. PubMed ID: 16468986 [TBL] [Abstract][Full Text] [Related]
18. Phenoxypropanolamine derivatives as selective inhibitors of the 20S proteasome β1 and β5 subunits. Hovhannisyan AA; Pham TH; Bouvier D; Tan X; Touhar S; Mkryan GG; Dallakyan AM; El Amri C; Melikyan GS; Reboud-Ravaux M; Bouvier-Durand M Bioorg Med Chem Lett; 2017 Dec; 27(23):5172-5178. PubMed ID: 29113763 [TBL] [Abstract][Full Text] [Related]
19. Structure-based design of human immuno- and constitutive proteasomes inhibitors. Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252 [TBL] [Abstract][Full Text] [Related]
20. Concise Chemoenzymatic Total Synthesis and Identification of Cellular Targets of Cepafungin I. Amatuni A; Shuster A; Adibekian A; Renata H Cell Chem Biol; 2020 Oct; 27(10):1318-1326.e18. PubMed ID: 32763140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]